Evidence map›Paper›PMID 34124851›Full record

ArticleBrain and behavior2021

Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study.

Khalid Orayj, Tahani Almeleebia, Easwaran Vigneshwaran, Sultan Alshahrani, Sirajudeen S Alavudeen, Wael Alghamdi

Open access · goldAbstract read
In one paragraph

Article in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. The pathobiological basis of depression in Parkinson disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Khalid OrayjDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0001-6651-2306
Tahani AlmeleebiaDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Easwaran VigneshwaranDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Sultan AlshahraniDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Sirajudeen S AlavudeenDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Wael AlghamdiDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
King Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAlthough depression symptoms are common among patients with Parkinson's disease (PD), the medical literature still reports underrecognition of depression in patients with PD. Our main objective is to examine the trend of depression recognition during the first year of PD diagnosis using large population data.

methodsWe conducted a population-based study of residents in Wales, using the Secure Anonymized Information Linkage (SAIL) Databank. We included newly diagnosed patients with PD aged 40 years or older with a first PD diagnosis between 2000 and 2015. Depression and antidepressants related data were extracted from SAIL. A series of multilevel logistic regressions were run to determine the factors affecting depression recognition. The results were presented using odds ratios (ORs) with 95% confidence intervals (CI).

resultsThe study included 6596 patients with PD. About 38% of patients had a recorded code of antidepressants, depression diagnosis, or both within the first year of PD diagnosis. There was a significant association of depression diagnosis, antidepressant use, or both with the year of PD diagnosis (OR 0.972, 95% CI 0.962-0.983). We also found that patients who used monoamine oxidase inhibitors (MAO-B inhibitors) were associated with a lower depression diagnosis, use antidepressants, or both, compared to those who did not use MAO-B inhibitors (OR 0.769, 95% CI 0.627-0.943).

conclusionThere is a slight decrease in depression recognition in PD patients between 2000 and 2015, which could be due to an increase in depression recognition during the prodromal phase of PD.

Indexed as

Parkinson DiseaseAntidepressive AgentsDepressionHumansLogistic ModelsMonoamine Oxidase InhibitorsAntidepressive AgentsMonoamine Oxidase Inhibitorsdepressionincidencenon-motor symptomsParkinson's diseaseprodromal

Identifiers

PMID34124851
PMCPMC8413829
OpenAlexW3171792569

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.